Wednesday, July 8, 2026

Drug profile · INN

caffeine citrate

caffeine citrate (BLECTIFOR) is a adenosine receptor antagonist. Associated with Viridian Pharma Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Nervous system (N06) N06BC01
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — caffeine citrate
US status
approved
Class
Nervous system (N06)
Route
ORAL
Patents
0
Programs
1
Data quality
0.89

Quick answer

caffeine citrate (BLECTIFOR) is a adenosine receptor antagonist. Associated with Viridian Pharma Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN caffeine citrate
Brand BLECTIFOR
Mechanism Adenosine receptor antagonist
Target Adenosine receptor
Therapeutic class Nervous system (N06)
Route ORAL
Formulation SOLUTION
ATC code N06BC01

Mechanism of action

Adenosine receptor antagonist

Primary target: Adenosine receptor

Approval history

Authority Status Date
FDA approved
EMA approved

Pipeline programs

  1. Caffeine citrate Phase 2 · BRIGHT MINDS BIOSCIENCES · Retinopathy of Prematurity

Related & competitor drugs

  1. adenosine Adenosine receptor agonist
  2. aminophylline Adenosine receptor antagonist
  3. aripiprazole Nervous system (N05)
  4. brexpiprazole Nervous system (N05)
  5. brivaracetam Nervous system (N03)
  6. bupivacaine Nervous system (N01)

Frequently asked questions

What is caffeine citrate?

caffeine citrate (BLECTIFOR) is a adenosine receptor antagonist. Associated with Viridian Pharma Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for caffeine citrate?

BLECTIFOR is a marketed brand name for caffeine citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of caffeine citrate?

caffeine citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.